Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million
Portfolio Pulse from
Royalty Pharma is acquiring a synthetic royalty on U.S. sales of Geron's RYTELO for $125 million.
November 07, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron Corporation will receive $125 million from Royalty Pharma for a synthetic royalty on RYTELO, providing immediate capital.
The $125 million cash infusion from Royalty Pharma provides Geron with immediate capital, which could be used for further development or operational needs.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Royalty Pharma is investing $125 million to acquire a synthetic royalty on Geron's RYTELO, potentially enhancing its revenue streams.
The acquisition of a synthetic royalty on RYTELO could enhance Royalty Pharma's revenue, as it provides a new income stream from Geron's product sales.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80